KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Opko Health (OPK) Research & Development: 2010-2025

Historic Research & Development for Opko Health (OPK) over the last 16 years, with Sep 2025 value amounting to $30.1 million.

  • Opko Health's Research & Development rose 4.55% to $30.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $121.7 million, marking a year-over-year increase of 29.20%. This contributed to the annual value of $105.2 million for FY2024, which is 17.44% up from last year.
  • Opko Health's Research & Development amounted to $30.1 million in Q3 2025, which was down 0.87% from $30.3 million recorded in Q2 2025.
  • Over the past 5 years, Opko Health's Research & Development peaked at $32.6 million during Q1 2023, and registered a low of $17.3 million during Q2 2022.
  • Over the past 3 years, Opko Health's median Research & Development value was $28.8 million (recorded in 2024), while the average stood at $26.0 million.
  • Per our database at Business Quant, Opko Health's Research & Development soared by 78.05% in 2023 and then plummeted by 32.72% in 2024.
  • Opko Health's Research & Development (Quarterly) stood at $21.0 million in 2021, then fell by 7.04% to $19.5 million in 2022, then dropped by 0.69% to $19.4 million in 2023, then soared by 56.88% to $30.4 million in 2024, then climbed by 4.55% to $30.1 million in 2025.
  • Its Research & Development stands at $30.1 million for Q3 2025, versus $30.3 million for Q2 2025 and $30.8 million for Q1 2025.